Liposomal Vitamin C: What the Trials Actually Show

Vitamin C is the one place where the liposomal argument stops being theoretical. There are now around ten human trials comparing liposomal to ordinary ascorbate, most of them randomised crossovers, and in 2025 they were pulled together in a scoping review by Anitra Carr — who has spent a career on vitamin C pharmacology and is not in the business of flattering supplement formats.

The findings are genuinely interesting, and they point in two directions at once. Liposomal delivery does raise blood levels. Nobody has yet shown that the extra does anything. Both halves of that sentence are worth understanding, because between them they tell you who this format is plausibly for.

Ordinary vitamin C has a ceiling, and it is a design feature

Your gut does not absorb vitamin C passively. It uses dedicated transporters — the sodium-dependent vitamin C transporters, SVCT1 in the intestine and SVCT2 in tissues — and transporters can be saturated. Past a certain intake the doors are all occupied, absorption efficiency falls, and the kidneys start filtering off the surplus.

The consequence is a plasma curve that flattens. In healthy people, intakes of roughly 100 to 200 mg a day already produce circulating concentrations of about 50 to 70 µmol/L, and pushing the oral dose much higher moves that number surprisingly little. This is not a flaw the industry discovered; it is homeostasis working. Your body defends a vitamin C set point and disposes of the rest.

Saturation kinetics · plasma ascorbate

Why swallowing more vitamin C stops working

Liposomes get in through a different door

This is the part of the rationale that holds up mechanically. If ordinary absorption is limited by a saturable transporter, then a route that does not use that transporter is not subject to the same ceiling. Liposomal ascorbate — vesicles that range from about 20 nm to over a micron depending on the product — can be taken up by mechanisms that do not depend on SVCT1 at all, endocytosis among them.

So the mechanism is not marketing. It is a plausible bypass of a real bottleneck, and it predicts exactly what the trials find: higher peaks than the same dose of plain ascorbic acid.

Ten studies, and what they agree on

Carr's review found ten studies published between 2016 and 2024, using doses ranging from 150 mg to 10 g and sampling windows from four to twenty-four hours. Nine of the ten reported higher bioavailability from the liposomal form: peak concentrations 1.2 to 5.4 times higher, and areas under the curve 1.3 to 7.2 times higher.

That is a wide spread, and the width is the story. These were not ten runs of the same experiment — they used vastly different formulations at doses varying by a factor of nearly seventy. One study, Mikirova and colleagues in 2019, found essentially nothing: a plasma AUC ratio of 1.03. The honest summary is that liposomal ascorbate usually raises short-term blood levels, by an amount that depends heavily on which product you bought.

Then there are the things that should temper your confidence. Every one of the ten studies had industry funding or authors employed by companies. Sample sizes ran from five to twenty-seven people. Most did not report baseline ascorbate concentrations, and two measured vitamin C with fluorescence or colourimetric kits rather than the more accurate HPLC methods.

The best-designed trial, and the question it did not ask

The most rigorous of the set is a 2024 double-blind, placebo-controlled crossover in twenty-seven adults, using a single 500 mg dose — notably restrained, given earlier studies used four to thirty-six grams. It is also one of the few where the product was actually verified to be what it claimed: the liposomal structure was confirmed by cryo-electron microscopy, which matters more than it sounds, because "liposomal" describes a structure and structures can simply be absent.

The results were consistent and modest. Peak plasma concentration was 27% higher than standard vitamin C, plasma AUC over 24 hours 21% higher, peak leukocyte concentration 20% higher, leukocyte AUC 8% higher — all at p<0.001. Getting more into white blood cells is arguably the more meaningful of those numbers, since that is where vitamin C does its work in immune tissue.

The trial was funded by the manufacturer of the formulation tested, which does not invalidate it but belongs in the summary. And it measured no functional outcome whatsoever. It established that more vitamin C arrives. It did not ask what the extra did.

The two studies that did ask found nothing

Only two of the ten trials looked past the blood level for a biological effect, and this is the uncomfortable part.

Davis and colleagues in 2016 — the study most often cited as proof that liposomal vitamin C works — found that liposomal and non-liposomal ascorbate gave equivalent protection against lipid oxidation after forearm ischaemia. A 2024 trial by McGarry and colleagues also measured antioxidant endpoints, and on Carr's reading of it, the small percentage rise in serum antioxidant potential at two hours did not translate into better protection against cellular or nucleic-acid oxidation. Worth noting that the trial's own framing of those numbers is considerably more enthusiastic than the reviewer's; when an independent reviewer and a study's sponsors describe the same dataset differently, that gap is itself information.

Two studies is not a verdict. But it is a pattern worth naming: the outcome that sells the product has been measured many times, and the outcome that would justify it has been measured twice, with null results both times. Carr's own list of research priorities is telling — she wants someone to measure urinary elimination, tissue uptake, and how long repletion lasts in genuinely depleted people, because as she puts it, it is not certain how much of these products is retained in the body rather than simply excreted.

So who is this actually for

Take the mechanism seriously and the answer follows. A saturable transporter is a real ceiling, and bypassing it is a real advantage — for someone who is actually short of vitamin C, or trying to restore a low level, or taking a dose high enough that ordinary absorption has already given up. In those situations getting more in is the entire point.

If you already eat fruit and vegetables and your plasma level sits comfortably on the plateau, the case is much thinner. Bypassing a ceiling you are not pressed against buys you a higher peak and, on the evidence so far, a more expensive stream of urine. That is not a scandal. It is just a poor reason to pay a premium.

What the format cannot do is change what the nutrient is for. Vitamin C contributes to the normal function of the immune system, and it does that whether it arrives in a vesicle or in an orange. Better delivery supports a normal role more reliably; it does not add a new one.

The bottom line

Liposomal vitamin C has the best evidence in this category and it is still narrower than the marketing implies. Higher peaks: well established, magnitude product-dependent, all of it industry-funded and short-term. Higher levels inside white blood cells: shown once, properly. Any functional consequence: measured twice, found twice to be absent. Worth it if you are repleting a deficit or pushing past the absorption ceiling on purpose; hard to justify if you are already replete.

If you want it, buy the version that tells you what it is — a named phospholipid, a stated dose, ideally some evidence the manufacturer characterised the particles. Agen's liposomal vitamin C and liposomal vitamin C with zinc both use phospholipid delivery, and both zinc and vitamin C contribute to the normal function of the immune system. For the mechanism underneath the format, see what your gut does to a liposome; for a compound where the delivery question is far less settled, quercetin; and for which nutrients have authorised immune roles at all, our guide to everyday immune support.